

FOCUS ON Molecular Pathology—*RET* Testing


There are a number of *RET* inhibitors which have shown activity in clinical trials for the treatment of non-small cell lung cancers and thyroid tumours. These are FDA approved and approval in Europe is likely in the near future. Therefore there is a need to introduce testing for *RET* rearrangements.

Dr Jaclyn Hechtman from Memorial Sloan Kettering Cancer Center, New York will review the current knowledge on targetable *RET* alterations and compare the different assays used to detect them.

Dr Jenni Fairley, GenQA will summarise the data from the last five years of GenQA EQA for *RET* testing. *RET* testing for rearrangements is included in both the lung cancer and thyroid cancer EQAs; the thyroid cancer EQA will also examine SNVs in the *RET* gene.

After the seminar there will be a LIVE Question and Answer session.

Register for the free webinar and live Q&A session before **19th March 2021** at:
<https://attendee.gotowebinar.com/register/1334003786457691407>



RET webinar

Monday 22nd March 2021, 4pm GMT

- Introduction to *RET*
- *RET* fusion detection
- Comparison of *RET* fusion detection methods
- Results of previous GenQA EQAs for *RET* testing
- LIVE questions and answer session

If you wish to submit a question for the Q&A session, then please email info@genqa.org
Registered participants will have priority access to the webinar for one month (if you are unable to join us on the day).

For further information on this EQA please contact us at info@genqa.org
This seminar is supported by Eli Lilly.

FOCUS ON next month:

**Prenatal Cytogenomics:
Diagnosis and mosaicism**